US62855J1043
© Globe Newswire
09.12.2025
MYGN
LISTED
NASDAQ
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
News Preview
Myriad Genetics will present new data in eight abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS)....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
MYGN
LISTED
NASDAQ
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
News Preview
Clairity, Myriad Genetics, and MagView announce a joint collaboration in an effort to identify more women at high risk for breast cancer....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.11.2025
MYGN
LISTED
NASDAQ
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
News Preview
Myriad Genetics management will participate in two upcoming healthcare conferences....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
10.11.2025
MYGN
LISTED
NASDAQ
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
News Preview
Myriad Genetics expanded MyRisk® Hereditary Cancer Test to include genes referenced in national oncology guidelines....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
03.11.2025
MYGN
LISTED
NASDAQ
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
News Preview
Myriad Genetics today announced financial results for its third quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
MYGN
LISTED
NASDAQ
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
News Preview
Faster initial remission and response, persistent benefit over six months Faster initial remission and response, persistent benefit over six months...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.10.2025
MYGN
LISTED
NASDAQ
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
News Preview
Myriad Genetics will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
MYGN
LISTED
NASDAQ
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
News Preview
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
MYGN
LISTED
NASDAQ
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
News Preview
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad’s molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell r...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
MYGN
LISTED
NASDAQ
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
News Preview
Results published in the Journal of Clinical Psychopharmacology Results published in the Journal of Clinical Psychopharmacology...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2025
MYGN
LISTED
NASDAQ
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
News Preview
SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.08.2025
MYGN
LISTED
NASDAQ
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
News Preview
SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
13.08.2025
MYGN
LISTED
NASDAQ
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
News Preview
Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
MYGN
LISTED
NASDAQ
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON MYRIAD...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
MYGN
LISTED
NASDAQ
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MYRIAD GENETICS, INC. (MYGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTE...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
MYGN
LISTED
NASDAQ
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON MYRIAD GENETICS, INC. (MYGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CL...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.04.2025
MYGN
LISTED
NASDAQ
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
News Preview
Podium presentation showcases the clinical application of Precise™ MRD Podium presentation showcases the clinical application of Precise™ MRD...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.04.2025
MYGN
LISTED
NASDAQ
Myriad Genetics Announces Inducement Awards
News Preview
SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the g...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.04.2025
MYGN
LISTED
NASDAQ
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
News Preview
Myriad Genetics announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
MYGN
LISTED
NASDAQ
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
News Preview
Myriad Genetics announced a collaboration with Gabbi to provide an integrated offering for breast cancer risk assessment....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
MYGN
LISTED
NASDAQ
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
News Preview
Myriad Genetics today announced financial results for its fourth quarter and full-year ended December 31, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.02.2025
MYGN
LISTED
NASDAQ
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
News Preview
Myriad Genetics will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.02.2025
MYGN
LISTED
NASDAQ
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
News Preview
Myriad Genetics announces it was granted two new patents for its Molecular Residual Disease (MRD) assay....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2025
MYGN
LISTED
NASDAQ
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
News Preview
Myriad Genetics announced it signed an agreement with sports broadcaster Hannah Storm to promote the importance of knowing family cancer history....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2025
MYGN
LISTED
NASDAQ
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2025
MYGN
LISTED
NASDAQ
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
MYGN
LISTED
NASDAQ
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
News Preview
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2024
MYGN
LISTED
NASDAQ
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
News Preview
Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2024
MYGN
LISTED
NASDAQ
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
News Preview
Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
MYGN
LISTED
NASDAQ
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
News Preview
Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium....
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
MYGN
LISTED
NASDAQ
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MY...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
MYGN
LISTED
NASDAQ
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
News Preview
Myriad Genetics announced SneakPeek is now available over the counter in more than 8,800 retail locations....
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
MYGN
LISTED
NASDAQ
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MY...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2024
MYGN
LISTED
NASDAQ
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
News Preview
Myriad Genetics, Inc. (NASDAQ: MYGN) will hold its third quarter earnings conference call on Thursday, Nov. 7, 2024 at 4:30 pm ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2024
MYGN
LISTED
NASDAQ
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
News Preview
Myriad Genetics and Flatiron Health partner to make genetic testing more accessible with EMR integration...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.10.2024
MYGN
LISTED
NASDAQ
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
News Preview
SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in breast cancer using Myriad’s Precise® MRD test....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2024
MYGN
LISTED
NASDAQ
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
News Preview
SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima’s UG 100™ s...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2024
MYGN
LISTED
NASDAQ
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
News Preview
SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) as...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.08.2024
MYGN
LISTED
NASDAQ
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
News Preview
SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2024
MYGN
LISTED
NASDAQ
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
News Preview
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2024
MYGN
LISTED
NASDAQ
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
News Preview
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual d...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2024
MYGN
LISTED
NASDAQ
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
News Preview
SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a second patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) a...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
MYGN
LISTED
NASDAQ
Myriad Genetics Earns 2024 Great Place To Work® Certification™
News Preview
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what current employees say about their experience working at Myriad....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.06.2024
MYGN
LISTED
NASDAQ
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
News Preview
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2024
MYGN
LISTED
NASDAQ
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
News Preview
VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.05.2024
MYGN
LISTED
NASDAQ
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
News Preview
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2024
MYGN
LISTED
NASDAQ
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
News Preview
Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2024
MYGN
LISTED
NASDAQ
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
News Preview
SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the United S...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
